Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background. Pirfenidone and nintedanib are the sole pharmacological therapies currently approved for idiopathic pulmonary fibrosis (IPF). Limited comparison data is available in literature, despite they are both prescribed for mild-to-moderate disease. Here, we describe our almost ten-years real-life experience with antifibrotic treatment to investigate potential differences in terms of efficacy. Population and methods. We retrospectively recruited patients diagnosed with IPF and treated with pirfenidone or nintedanib at Siena Referral Centre. Clinical, functional, safety and radiological data was collected at baseline and during the follow-up, according to our Centre protocol. Results. We retrospectively recruited 263 IPF patients (139 treated with pirfenidone and 124 with nintedanib) in the study. After 885.3 ± 559.5 days of observation, the median survival was 1224 days. No significant differences were found between pirfenidone and nintedanib in terms of survival and time to decline of forced vital capacity > 10% (p=0.8786 and p=0.1677, respectively). A smaller lung diffusion for carbon monoxide (DLCO) decrease was found after one year of therapy with nintedanib in respect to pirfenidone (p=0,0167). Overall, 21 patients permanently discontinued antifibrotic treatment due to side effects (14 with pirfenidone, 7 with nintedanib); no fatal adverse events were recorded. Discussion. Our results showed a similar effectiveness between pirfenidone and nintedanib in terms of mortality and functional disease progression. Both drugs confirmed their good tolerability profile and no new safety alerts were observed. Nintedanib was associated with a smaller reduction of DLCO after one year of follow-up compared with pirfenidone, maybe due to its antiangiogenic properties.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, L., Ryerson, C. J., Lederer, D. J., Behr, J., Cottin, V., Danoff, S. K., Morell, F., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1255st · Cited by 4,103 · cited 1×
“Despite the limitations of our retrospective study, our results may suggest that nintedanib has a specific effect on slowing the decline in lung diffusion capacity with respect to pirfenidone, probably due to its well-known antiangiogenic properties (Hilberg et al., 2008; Reck, 2015).”
ResultA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung
Graham, B. L., Brusasco, V., Burgos, F., Cooper, B. G., Jensen, R., Kendrick, A., MacIntyre, N. R., Thompson, B. R., & Wanger, J. (2017) · European Respiratory Journal · doi:10.1183/13993003.00016-2016 · Cited by 972
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
Lancaster, L. H., de Andrade, J. A., Zibrak, J. D., Padilla, M. L., Albera, C., Nathan, S. D., Wijsenbeek, M. S., Stauffer, J. L., Kirchgaessler, K.-U., & Costabel, U. (2017) · European Respiratory Review · doi:10.1183/16000617.0057-2017 · Cited by 295 · cited 4×
“Concerning mortality, our data showed a median survival of 1224 days, similar to that of previous reports (Margaritopoulos et al., 2018; Antoniou et al., 2020; Vietri et al., 2020).”
BackgroundResultInfluentialLancaster, L., Crestani, B., Hernandez, P., Inoue, Y., Wachtlin, D., Loaiza, L., Quaresma, M., Stowasser, S., & Richeldi, L. (2019) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2018-000397 · Cited by 209
Rogliani, P., Calzetta, L., Cavalli, F., Matera, M. G., & Cazzola, M. (2016) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2016.07.009 · Cited by 168
Cited by
Idiopathic pulmonary fibrosis: Current and future treatment
Glass, D. S., Grossfeld, D., Renna, H. A., Agarwala, P., Spiegler, P., DeLeon, J., & Reiss, A. B. (2022) · The Clinical Respiratory Journal · doi:10.1111/crj.13466 · Cited by 314
Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis
Petnak, T., Lertjitbanjong, P., Thongprayoon, C., & Moua, T. (2021) · Chest · doi:10.1016/j.chest.2021.06.049 · Cited by 220
Takehara, K., Koga, Y., Hachisu, Y., Utsugi, M., Sawada, Y., Saito, Y., Yoshimi, S., Yatomi, M., Shin, Y., Wakamatsu, I., et al. (2022) · Cells · doi:10.3390/cells11010143 · Cited by 64
Comparison of Pirfenidone and Nintedanib
Kim, J. S., Murray, S., Yow, E., Anstrom, K. J., Kim, H. J., Flaherty, K. R., Martinez, F. J., & Noth, I. (2024) · CHEST · doi:10.1016/j.chest.2023.11.035 · Cited by 34
Metadata
- Authors
- Cameli, P., Refini, R. M., Bergantini, L., d’Alessandro, M., Alonzi, V., Magnoni, C., Rottoli, P., Sestini, P., & Bargagli, E.
- Venue
- Frontiers in Molecular Biosciences
- Publisher
- Frontiers Media SA
- Published
- 2020-09-04
- Volume
- 7
- Pages
- 581828-581828
- ISSN
- 2296-889X (ISSN-L)
- OpenAlex
- W3083040024
- Cited by
- 89
- References
- 9
- FWCI
- 6.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.